For a company many in the industry probably haven't heard of, Light Sciences Oncology has big ambitions. The Bellevue, Wash., biotech thinks its lead program, Aptocine , a drug/device combination product in Phase III, rapidly will become the primary choice for first-line therapy in a range of solid tumors following FDA approval. Despite that nervy goal, the privately held company - which since its inception in 2005 has raised roughly $137 million, largely from venture capital investors - is emerging...